Literature DB >> 32328966

High rate incidence of post-surgical adverse events in patients with low-risk papillary thyroid cancer who did not accept active surveillance.

Anabella Smulever1, Fabián Pitoia2.   

Abstract

PURPOSE: To describe the outcomes and the incidence of adverse events following active surveillance (AS) versus immediate surgery in patients with low-risk papillary thyroid carcinoma (PTC).
METHODS: We prospectively evaluated 286 patients who attended the Hospital de Clínicas, with a single thyroid nodule <1.5 cm classified as Bethesda category V or VI (PTC). Those patients with no aggressive features were considered as harboring a low-risk PTC and were offered AS or immediate surgery. For patients who opted for AS, surgery was recommended if tumor progression was observed. Post-operative adverse events were recorded for those patients treated with surgery (after AS or immediate surgery).
RESULTS: From 286 eligible patients, 164 harbored a low-risk PTC. Among these, 75% (n = 123) underwent immediate surgery and 25% (n = 41) opted for AS. Within the last group, increase in tumor size more than 3 mm was observed in 14.6 and 4.8% was diagnosed with lymph-node metastases after a median of 37.5 months (range, 12-65) of follow-up. One hundred and thirty five patients underwent surgery: in 123, it was immediate after diagnosis and in 12 after a median of 35 months (range, 12-65) of AS. Both groups had excellent oncological outcomes. The frequency of postoperative adverse events was 24.4%, which was permanent in 9.6% of cases. The immediate-surgery group presented higher incidence of permanent vocal cord paralysis (2.4 vs. 0%); permanent hypoparathyroidism (5.7 vs. 0%) and local complications (4 vs. 2.4%) compared with the AS group, all non-statistically significant.
CONCLUSIONS: The high incidence of postoperative complications observed in our media could be avoided if AS was performed as the initial approach in patients with low-risk PTCs. The frequency of tumor growth and LN metastases during AS was similar to other series.

Entities:  

Keywords:  Active surveillance; Adverse events; Hypoparathyroidism; Low-risk papillary thyroid carcinoma; Surgery; Vocal cord paralysis

Mesh:

Year:  2020        PMID: 32328966     DOI: 10.1007/s12020-020-02310-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  1 in total

1.  Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America.

Authors:  Anabella Smulever; Fabián Pitoia
Journal:  Arch Endocrinol Metab       Date:  2019-09-02       Impact factor: 2.309

  1 in total
  4 in total

Review 1.  What are the real rates of temporary hypoparathyroidism following thyroidectomy? It is a matter of definition: a systematic review.

Authors:  Georgios D Koimtzis; Leandros Stefanopoulos; Kleanthis Giannoulis; Theodosios S Papavramidis
Journal:  Endocrine       Date:  2021-03-02       Impact factor: 3.633

Review 2.  Thermal Ablation for Papillary Thyroid Microcarcinoma: How Far We Have Come?

Authors:  Yu Min; Xing Wang; Hang Chen; Jialin Chen; Ke Xiang; Guobing Yin
Journal:  Cancer Manag Res       Date:  2020-12-24       Impact factor: 3.989

3.  The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.

Authors:  Xiaojuan Zha; Zhenchun Miao; Xiu Huang; Xingchun Wang; Ruting Xie; Jiaoying Jin; Dajin Zou; Peng Yang; Yueye Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-07       Impact factor: 5.555

Review 4.  Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival.

Authors:  Jolanta Krajewska; Aleksandra Kukulska; Malgorzata Oczko-Wojciechowska; Agnieszka Kotecka-Blicharz; Katarzyna Drosik-Rutowicz; Malgorzata Haras-Gil; Barbara Jarzab; Daria Handkiewicz-Junak
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-06       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.